Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2008;117:2253-2261
Published online before print April 21, 2008, doi: 10.1161/CIRCULATIONAHA.107.748640
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
117/17/2253    most recent
CIRCULATIONAHA.107.748640v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Guo, C.
Right arrow Articles by Adler, G. K.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guo, C.
Right arrow Articles by Adler, G. K.
Related Collections
Right arrow Obesity
Right arrow Type 2 diabetes
Right arrow Animal models of human disease
Right arrow Energy metabolism
Right arrow Growth factors/cytokines
Right arrow Physiological and pathological control of gene expression
Right arrowRelated Article

(Circulation. 2008;117:2253-2261.)
© 2008 American Heart Association, Inc.


Molecular Cardiology

Mineralocorticoid Receptor Blockade Reverses Obesity-Related Changes in Expression of Adiponectin, Peroxisome Proliferator-Activated Receptor-{gamma}, and Proinflammatory Adipokines

Christine Guo, MD; Vincent Ricchiuti, PhD; Bill Q. Lian, MD, PhD; Tham M. Yao, BSc; Patricia Coutinho, BSc; José R. Romero, PhD; Jianmin Li, MS; Gordon H. Williams, MD; Gail K. Adler, MD, PhD

From the Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women’s Hospital (C.G., V.R., T.M.Y., P.C., J.R.R., J.L., G.H.W., G.K.A.), and Department of Medicine, Mount Auburn Hospital (B.Q.L.), Harvard Medical School, Boston, Mass.

Reprint requests to Gail K. Adler, MD, PhD, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women’s Hospital, 221 Longwood Ave, Boston MA 02115. E-mail gadler{at}partners.org

Received November 1, 2007; accepted February 26, 2008.

Background— In obesity, decreases in adiponectin and increases in proinflammatory adipokines are associated with heart disease. Because adipocytes express mineralocorticoid receptor (MR) and MR blockade reduces cardiovascular inflammation and injury, we tested the hypothesis that MR blockade reduces inflammation and expression of proinflammatory cytokines in adipose tissue and increases adiponectin expression in adipose tissue and hearts of obese mice.

Methods and Results— We determined the effect of MR blockade (eplerenone, 100 mg/kg per day for 16 weeks) on gene expression in retroperitoneal adipose and heart tissue from obese, diabetic db/db mice (n=8) compared with untreated obese, diabetic db/db mice (n=10) and lean, nondiabetic db/+ littermates (n=11). Expression of tumor necrosis factor-{alpha}, monocyte chemoattractant protein-1, plasminogen activator inhibitor type 1, and macrophage protein CD68 increased, and expression of adiponectin and peroxisome proliferator-activated receptor-{gamma} decreased in retroperitoneal adipose tissue from obese versus lean mice. In addition, adiponectin expression in heart was reduced in obese versus lean mice. MR blockade prevented these obesity-related changes in gene expression. Furthermore, treatment of undifferentiated preadipocytes with aldosterone (10–8 mol/L for 24 hours) increased mRNA levels of tumor necrosis factor-{alpha} and monocyte chemoattractant protein-1 and reduced mRNA and protein levels of peroxisome proliferator-activated receptor-{gamma} and adiponectin, supporting a direct aldosterone effect on gene expression.

Conclusions— MR blockade reduced expression of proinflammatory and prothrombotic factors in adipose tissue and increased expression of adiponectin in heart and adipose tissue of obese, diabetic mice. These effects on adiponectin and adipokine gene expression may represent a novel mechanism for the cardioprotective effects of MR blockade.


 

CLINICAL PERSPECTIVE


Related Article:

Clinical Summaries
Circulation 2008 117: 2169. [Full Text]